Chongqing Xishan Science and Technology Co.
Sponsor (lead underwriter): Orient Securities Underwriting and Sponsoring Co.
Company Profile:
Xishan Science and Technology focuses on surgical medical equipment, especially minimally invasive surgical medical equipment, mainly engaged in the research and development of surgical power devices, The main products include surgical power unit, consumables and accessories, etc. Currently, the products are mainly used in neurosurgery, otorhinolaryngology, orthopedics, breast surgery and other clinical departments.
The controlling shareholder of Xishan Technology is Chongqing Xishan Investment Co. As of the end of the reporting period, Xishan Investment directly holds 48.08% of the company's shares. As of May 18, 2023, Guo Yijun directly holds 1,638,200 shares of the company, the shareholding ratio of 4.12%; Guo Yijun, Li Daihong and his wife hold 100.00% of the equity of Xishan Investment, Xishan Investment directly holds 1,911,300 shares of the company, the shareholding ratio of 48.08% of the equity; Guo Yijun is the concentricity of the investment, the happiness of the executive affairs partner ( Guo Yijun is the executive partner (GP) of Tongxin Investment and Happiness Investor, and Tongxin Investment and Happiness Investor hold 2,314,300 shares and 641,000 shares of the Company respectively, with shareholding ratio of 5.82% and 1.61% respectively. In summary, Guo Yijun and Li Daihong together control 59.64% of the company's voting rights (corresponding to 23.778 million shares), and are the company's de facto controllers. During the reporting period, there was no change in the actual controller of the Company.
Xishan Science and Technology on May 18, 2023 issued a prospectus shows that the company intends to raise funds 66,123.45 million yuan for the industrialization of the surgical power system project, research and development center construction project, information technology construction project, marketing and service network upgrading project, supplementary working capital.
Xishan Science and Technology May 25, 2023 release of the initial public offering of shares and listed on the Science and Technology Board issuance announcement shows that the fund-raising project is expected to use the amount of proceeds of 66,123.45 million yuan. Based on the issue price of RMB135.80 per share and the number of new shares issued of 13,250,367,000 shares, if the issue is successful, the Company is expected to raise a total of RMB1,799,399,800,000, and after deducting approximately RMB167,871,200,000 (excluding value-added tax) in issuance costs, the net proceeds are expected to amount to RMB1,631,528,600,000 (if there is any difference in rounding up, due to rounding off).